Core Insights - Femasys Inc. has made significant progress in clinical, regulatory, and commercial milestones for its FemBloc and FemaSeed products, with ongoing enrollment in the pivotal FINALE clinical trial for FemBloc aimed at U.S. FDA approval [3][5] - The company reported a 40.8% increase in sales for 2025, primarily driven by FemBloc, and has sufficient cash to fund operations into the third quarter of 2026 [6][7] Corporate Highlights - Initiated patient enrollment in the FINALE pivotal clinical trial for FemBloc, a key step toward U.S. approval [5] - Expanded FemaSeed commercialization in the U.S. with the introduction of the FemSperm product family [3] - Appointed Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors to strengthen leadership [5] - Achieved certification for FemBloc under the Medical Device Single Audit Program (MDSAP) [5] - Received approval for a new Category III CPT code for FemaSeed, supporting future reimbursement pathways [5] - Entered a strategic distribution partnership with OR Consulting for product launches in Switzerland [5] - Established a partnership with Refuah Health Center to advance FemaSeed adoption in community-based care [5] - Secured FDA 510(k) clearance for the FemVue Controlled device [5] - Completed $12 million financing to strengthen the balance sheet [5] - Initiated a European post-market surveillance study for FemBloc [5] Financial Results - Sales increased by $664,205 to $2,293,313 in 2025 from $1,629,108 in 2024 [6] - Research and development expenses decreased by $638,839 to $7,577,704 in 2025 compared to $8,216,543 in 2024 [6] - Net loss for 2025 was $18,627,887, or ($0.47) per share, compared to a net loss of $18,816,628, or ($0.85) per share in 2024 [6][15] - Cash and cash equivalents as of December 31, 2025, were approximately $9.3 million, with an accumulated deficit of approximately $145.8 million [6][7] Product and Market Information - FemBloc is the first non-surgical, in-office alternative to surgical sterilization, receiving full regulatory approval in Europe, the UK, and New Zealand in 2025 [17] - FemaSeed is a first-line infertility treatment that has demonstrated more than double the pregnancy rate of traditional IUI [16][17] - The FemSperm product line enables in-office sperm preparation and analysis for infertility treatment [3][16]

Core Insights - Femasys Inc. has appointed Dr. Kenneth D. Eichenbaum to its Board of Directors, bringing over 20 years of experience in evaluating biotechnology and medical device companies [1][2] - Dr. Eichenbaum's clinical and financial expertise is expected to enhance Femasys' strategic direction as the company continues to innovate in women's health [2] - The company is focused on making fertility and non-surgical permanent birth control more accessible and cost-effective through its patented products [3] Company Overview - Femasys is a biomedical innovator with a portfolio of therapeutic and diagnostic products aimed at improving women's reproductive health [3] - The company's lead products include FemaSeed, FemSperm, and FemVue, with FemaSeed demonstrating more than double the pregnancy rates of traditional IUI [3] - FemBloc, a non-surgical permanent birth control method, received regulatory approval in Europe, the UK, and New Zealand, and is set for commercialization through strategic partnerships [4] Product Innovations - FemaSeed is a groundbreaking infertility treatment, while FemSperm is a sperm preparation and analysis product line [3] - FemBloc is the first non-surgical alternative to surgical sterilization, with initial clinical trials showing compelling effectiveness and high satisfaction rates [4] - The FemChec diagnostic product provides an ultrasound-based test to confirm procedural success, further enhancing the patient experience [4]

Core Insights - Femasys Inc. has initiated patient enrollment in the FINALE pivotal trial for FemBloc, a non-surgical permanent birth control solution, following FDA approval based on positive clinical data [1][2] - FemBloc is already being commercialized in Europe and other countries, aiming to provide a safer and more accessible alternative to surgical sterilization [1][2] Company Overview - Femasys is focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a broad portfolio of patented therapeutic and diagnostic products [4] - The company has received regulatory approvals for FemBloc in Europe, the UK, and New Zealand, with plans for strategic partnerships to enhance commercialization [5][6] FINALE Trial Details - The FINALE trial is a prospective, multi-center, open-label study assessing the safety and effectiveness of FemBloc, with an initial roll-in enrollment of 50 women completed [3] - The primary endpoint of the trial is the pregnancy rate after one year of using FemBloc, with an interim analysis planned after 300 participants complete one year [3] Product Features - FemBloc utilizes a patented delivery system to place a proprietary blended polymer into the fallopian tubes, forming natural scar tissue for permanent occlusion [2] - This non-surgical method aims to reduce procedural risks and healthcare costs associated with traditional surgical sterilization [2]

Core Viewpoint - Femasys Inc. has granted stock options to two new non-executive employees as part of their employment inducement strategy, reflecting the company's commitment to expanding its workforce and enhancing its innovative capabilities in the biomedical sector [1][2]. Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally through a broad, patent-protected portfolio of therapeutic and diagnostic products [3]. - The company is actively commercializing its lead product innovations in the U.S. and key international markets, with a focus on enhancing fertility treatment options and permanent birth control solutions [3]. Product Innovations - Femasys' fertility portfolio includes: - FemaSeed Intratubal Insemination (ITI), which has demonstrated more than double the pregnancy rates of traditional IUI with a comparable safety profile [3]. - FemSperm, a sperm preparation and analysis product line [3]. - FemVue, a companion diagnostic for fallopian tube assessment [3]. - FemBloc is the first and only non-surgical, in-office alternative to surgical sterilization, receiving full regulatory approval in Europe, the UK, and New Zealand in 2025 [4]. - The FemChec diagnostic product provides an ultrasound-based test to confirm procedural success, with initial clinical trials showing compelling effectiveness and high satisfaction rates [4]. Stock Options and Employment Strategy - Femasys granted options to purchase 185,000 shares at exercise prices of $0.50 and $0.57, equal to the closing stock price on the employment date [2]. - The stock options will vest 25% on the first anniversary of employment, with the remaining shares vesting 25% each year over the next three years, contingent on continued employment [2].

Core Insights - Femasys Inc. has announced that its FemBloc permanent birth control system has achieved MDSAP certification, which will facilitate regulatory and commercial execution in key global markets [1][2] - The MDSAP certification enhances the company's manufacturing credibility and operational scalability, supporting ongoing commercialization in Europe and enabling market entry in additional high-value regions [1][2] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally through a patent-protected portfolio of products [3] - The company is actively commercializing its lead product innovations in the U.S. and key international markets, including a fertility portfolio that features FemaSeed, FemSperm, and FemVue [3] Product Details - FemBloc is a non-surgical solution for permanent birth control that addresses the unmet need in women's reproductive health by using a patented delivery system to create natural scar tissue for permanent occlusion [2][4] - The product has received full regulatory approval in Europe, the UK, and New Zealand, and its commercialization will be completed through strategic partnerships in select European countries [4]

Core Insights - Femasys Inc. has received approval from the American Medical Association (AMA) for a new Category III CPT code for its FemaSeed intratubal insemination (ITI) procedure, which is set to take effect on January 1, 2027, enhancing reimbursement strategies and patient access to this infertility treatment [1][2] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a patent-protected portfolio of therapeutic and diagnostic products [3] - The company's fertility portfolio includes FemaSeed ITI, FemSperm, and FemVue, with FemaSeed demonstrating more than double the pregnancy rates of traditional intrauterine insemination (IUI) in clinical trials [3] Product Details - FemaSeed is designed to improve fertilization by delivering sperm directly to the fallopian tube, offering a less invasive and more cost-effective alternative to traditional IUI and in vitro fertilization (IVF) [2] - FemBloc, another product, is the first non-surgical, in-office alternative to surgical sterilization, receiving regulatory approval in Europe, the UK, and New Zealand in 2025 [4] Market Strategy - The approval of the CPT code is expected to support broader clinical adoption and provider utilization of FemaSeed, aiming to reach over 10 million women in the U.S. affected by infertility [2] - Femasys plans to expand its provider footprint and accelerate adoption through the rollout of FemaSeed and the availability of its FemSperm product line [2]

Core Viewpoint - Femasys Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share, now having until July 13, 2026, to meet this requirement [1][2]. Company Compliance Status - The extension does not affect the continued listing status of Femasys' common stock on Nasdaq, and compliance will be confirmed if the stock price remains at or above $1.00 for ten consecutive business days [2]. - Femasys is committed to regaining compliance and plans to monitor its share price closely, taking necessary actions within the extension period [3]. Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a patent-protected portfolio of therapeutic and diagnostic products [4]. - The company's fertility portfolio includes FemaSeed, which is over twice as effective as traditional IUI, and FemVue, a diagnostic tool for fallopian tube assessment [4]. - FemBloc, a non-surgical permanent birth control method, received regulatory approval in Europe, the UK, and New Zealand in 2025, and is being commercialized through strategic partnerships [5].

Core Insights - Femasys Inc. has announced a partnership with Refuah Health Center to enhance the adoption of FemaSeed, a fertility treatment, within community-based healthcare settings [1][2] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a patent-protected portfolio of therapeutic and diagnostic products [4] - The company’s lead product, FemaSeed, is a next-generation artificial insemination solution that has shown over double the pregnancy rates compared to traditional intrauterine insemination (IUI) in cases of low male sperm count [3][4] Product Details - FemaSeed is designed to deliver sperm directly to the fallopian tube, providing a safe, accessible, and cost-effective first-line treatment option before in vitro fertilization (IVF) [3] - The product is authorized for use in multiple regions, including the U.S., Europe, UK, Canada, and Israel [3] Partnership Impact - The collaboration with Refuah Health Center aims to expand patient access to FemaSeed, thereby increasing its utilization as a first-line approach in infertility treatment [1][2] - Refuah Health Center, a Federally Qualified Community Health Center, emphasizes providing evidence-based options to streamline the fertility journey for patients [7]

Core Insights - Femasys Inc. has received FDA 510(k) clearance for its FemVue Controlled device, which integrates FemVue and FemChec technologies to enhance fallopian tube evaluation and improve workflow efficiency [1][2] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a patent-protected portfolio of therapeutic and diagnostic products [3] - The company is actively commercializing its lead product innovations in the U.S. and key international markets, including FemaSeed and FemVue [3] Product Details - The FemVue Controlled device is designed for controlled delivery of saline and air as contrast media during ultrasound imaging to evaluate fallopian tube status, enabling multiple clinical uses in one solution [2] - Femasys' fertility portfolio includes FemaSeed, which is over twice as effective as traditional intrauterine insemination (IUI) with a comparable safety profile [3] Recent Developments - FemBloc, a non-surgical permanent birth control method, received full regulatory approval in Europe, the UK, and New Zealand in 2025, with commercialization planned through strategic partnerships [4] - The FemChec product provides an ultrasound-based test to confirm procedural success, demonstrating compelling effectiveness and high satisfaction rates in initial clinical trials [4]

Core Insights - Femasys Inc. has achieved significant regulatory milestones, including FDA IDE approval for the final pivotal trial of FemBloc, which positions the company for potential U.S. FDA approval [3][5][19] - The company secured $12 million in financing, enhancing its balance sheet and extending its cash runway, with total potential funding of $58 million if all warrants are exercised [5][7] - Sales for the third quarter of 2025 increased by 31.4% to $729,394, driven primarily by FemBloc sales, while R&D expenses decreased significantly [6][12] Regulatory Approvals - Femasys received regulatory approvals for the complete FemBloc System in the U.K. and New Zealand, expanding access to this non-surgical permanent birth control option [3][5][19] - Initial commercial orders have been received from distribution partners in Spain and France, indicating early momentum in the European market [3][5] Financial Performance - For the third quarter of 2025, sales increased by $174,486 to $729,394 compared to the same period in 2024, primarily due to FemBloc [6] - R&D expenses decreased by 40.0% to $1,382,022, reflecting a shift towards commercialization and reduced costs [6] - The net loss for the third quarter was $4,194,821, or ($0.10) per share, an improvement from a net loss of $5,408,860, or ($0.24) per share, in the prior year [6] Cash Position - As of September 30, 2025, Femasys had approximately $4.6 million in cash and cash equivalents, with an accumulated deficit of approximately $141.9 million [7] - The company expects its current cash position, bolstered by recent financing, to fund operations into September 2026 [7] Strategic Partnerships - Femasys announced a partnership with Kebomed to commercialize FemBloc in France and the Benelux region, enhancing its distribution capabilities [5] - A partnership with Medical Electronic Systems LLC was established to provide the FemSperm™ Analysis Kit, further expanding the company's product offerings [5]